Sanofi: Should Value Investors Consider SNY Stock?

Broad Value Outlook

In aggregate, Sanofi currently has a Zacks Value Style Score of ‘B', putting it into the top 40% of all stocks we cover from this look. This makes Sanofi a solid choice for value investors.

What About the Stock Overall?

Though Sanofi might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘F' and a Momentum score of ‘C'. This gives SNY a Zacks VGM score—or its overarching fundamental grade—of ‘C'. (You can read more about the Zacks Style Scores here >>)

Notably, the company's recent earnings estimates have been somewhat encouraging. Both, the current quarter and full year estimates have seen one upward revision each, compared with no downward revisions, in the last 60 days.

This has had a meaningful impact on the consensus estimate as the current quarter consensus estimate has risen by 12.9% in the past two months, while the full year estimate has inched higher by 3.2%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

Sanofi Price and Consensus

Sanofi Price and Consensus | Sanofi Quote

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.  See the pot trades we're targeting>>